Fortitude Family Office’s Zenas BioPharma ZBIO Stock Holding History

Fortitude Family Office’s Portfolio ZBIO Stock Details ZBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$782	Hold	29	–	–	﹤0.01%	2302
2026 Q2	$736	Buy	+29	New	+$576	﹤0.01%	1864

Other funds holding ZBIO

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

IFS Advisors Overland Park, Kansas $332M AUM 8.56% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Fortitude Family Office's ZBIO Position: Q3 2026 in Review

Fortitude Family Office held its Zenas BioPharma (ZBIO) position steady in Q3 2026 at 29 shares worth $782. The position accounts for ﹤0.01% of the portfolio, ranked #2302.

Fortitude Family Office first reported a position in ZBIO in Q2 2026 and has held it in 2 quarters since. 6 funds tracked by Wall St. Rank hold ZBIO as of Q3 2026.

Fortitude Family Office held 29 shares of Zenas BioPharma worth $782 as of Q3 2026.
Fortitude Family Office left its Zenas BioPharma share count unchanged in Q3 2026.
Zenas BioPharma made up ﹤0.01% of Fortitude Family Office's portfolio in Q3 2026, its #2302 holding.
Fortitude Family Office first reported a position in Zenas BioPharma in Q2 2026 and has held it in 2 quarters since.
6 funds tracked by Wall St. Rank held Zenas BioPharma as of Q3 2026.

Based on Fortitude Family Office's 13F filing for Q3 2026, filed 14 Oct 2026.